HC Wainwright Issues Pessimistic Outlook for CMPX Earnings

Compass Therapeutics, Inc. (NASDAQ:CMPX) – Stock analysts at HC Wainwright lowered their Q2 2025 earnings per share estimates for Compass Therapeutics in a research note issued to investors on Thursday, May 8th. HC Wainwright analyst J. Pantginis now expects that the company will earn ($0.13) per share for the quarter, down from their prior forecast of ($0.12). HC Wainwright currently has a “Buy” rating and a $24.00 target price on the stock. The consensus estimate for Compass Therapeutics’ current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Compass Therapeutics’ Q3 2025 earnings at ($0.14) EPS, FY2025 earnings at ($0.54) EPS, FY2026 earnings at ($0.57) EPS, FY2027 earnings at ($0.48) EPS and FY2028 earnings at ($0.18) EPS.

CMPX has been the topic of a number of other research reports. Leerink Partners upgraded Compass Therapeutics from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $4.00 to $6.00 in a research note on Wednesday, April 2nd. Piper Sandler began coverage on Compass Therapeutics in a report on Wednesday, February 19th. They issued an “overweight” rating and a $12.00 price target for the company. Wedbush reaffirmed an “outperform” rating and issued a $8.00 price target on shares of Compass Therapeutics in a report on Tuesday, April 1st. D. Boral Capital reaffirmed a “buy” rating and issued a $32.00 price target on shares of Compass Therapeutics in a report on Monday, April 28th. Finally, Jefferies Financial Group upped their price target on Compass Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, February 10th. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $13.13.

Compass Therapeutics Stock Down 0.5%

Shares of CMPX opened at $2.00 on Monday. Compass Therapeutics has a 52 week low of $0.77 and a 52 week high of $4.08. The company has a market capitalization of $276.57 million, a price-to-earnings ratio of -5.41 and a beta of 1.40. The stock’s 50-day moving average price is $1.97 and its 200-day moving average price is $2.10.

Compass Therapeutics (NASDAQ:CMPX) last issued its earnings results on Thursday, May 8th. The company reported ($0.12) EPS for the quarter, hitting analysts’ consensus estimates of ($0.12).

Insider Buying and Selling at Compass Therapeutics

In other news, insider Jonathan Anderman bought 20,000 shares of Compass Therapeutics stock in a transaction on Monday, April 7th. The stock was acquired at an average price of $1.54 per share, with a total value of $30,800.00. Following the completion of the acquisition, the insider now directly owns 21,000 shares of the company’s stock, valued at $32,340. The trade was a 2,000.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Carl L. Gordon sold 3,571,428 shares of the stock in a transaction that occurred on Wednesday, April 9th. The shares were sold at an average price of $1.59, for a total value of $5,678,570.52. The disclosure for this sale can be found here. Insiders own 28.50% of the company’s stock.

Hedge Funds Weigh In On Compass Therapeutics

A number of hedge funds have recently made changes to their positions in the company. Enavate Sciences GP LLC acquired a new stake in shares of Compass Therapeutics in the fourth quarter valued at approximately $11,293,000. Tang Capital Management LLC increased its holdings in shares of Compass Therapeutics by 225.4% in the fourth quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company’s stock valued at $8,555,000 after purchasing an additional 4,087,005 shares during the last quarter. MPM Bioimpact LLC increased its holdings in shares of Compass Therapeutics by 51.9% in the fourth quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company’s stock valued at $12,423,000 after purchasing an additional 2,926,002 shares during the last quarter. SG Americas Securities LLC increased its holdings in shares of Compass Therapeutics by 138.2% in the first quarter. SG Americas Securities LLC now owns 940,784 shares of the company’s stock valued at $1,787,000 after purchasing an additional 545,767 shares during the last quarter. Finally, Nuveen LLC acquired a new stake in shares of Compass Therapeutics in the first quarter valued at approximately $579,000. Institutional investors and hedge funds own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.